<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2019-05-20" updated="2019-11-05">
  <drugbank-id primary="true">DB14783</drugbank-id>
  <name>Diroximel fumarate</name>
  <description>Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life.[A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS.[A187535]&#13;
&#13;
Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS.  This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and approved by the FDA on October 30, 2019.[L9626]</description>
  <cas-number>1577222-14-0</cas-number>
  <unii>K0N0Z40J3W</unii>
  <average-mass>255.226</average-mass>
  <monoisotopic-mass>255.074287143</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A187529</ref-id>
        <pubmed-id>29410647</pubmed-id>
        <citation>Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y: Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Front Neurol. 2018 Jan 23;9:5. doi: 10.3389/fneur.2018.00005. eCollection 2018.</citation>
      </article>
      <article>
        <ref-id>A187532</ref-id>
        <pubmed-id>31538304</pubmed-id>
        <citation>Palte MJ, Wehr A, Tawa M, Perkin K, Leigh-Pemberton R, Hanna J, Miller C, Penner N: Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. Adv Ther. 2019 Nov;36(11):3154-3165. doi: 10.1007/s12325-019-01085-3. Epub 2019 Sep 19.</citation>
      </article>
      <article>
        <ref-id>A176474</ref-id>
        <pubmed-id>28367411</pubmed-id>
        <citation>Ghasemi N, Razavi S, Nikzad E: Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017 Apr-Jun;19(1):1-10. Epub 2016 Dec 21.</citation>
      </article>
      <article>
        <ref-id>A187535</ref-id>
        <pubmed-id>24722325</pubmed-id>
        <citation>Dutta R, Trapp BD: Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014 Jun;27(3):271-8. doi: 10.1097/WCO.0000000000000094.</citation>
      </article>
      <article>
        <ref-id>A187541</ref-id>
        <pubmed-id>24139424</pubmed-id>
        <citation>Sheikh SI, Nestorov I, Russell H, O'Gorman J, Huang R, Milne GL, Scannevin RH, Novas M, Dawson KT: Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013 Oct;35(10):1582-1594.e9. doi: 10.1016/j.clinthera.2013.08.009.</citation>
      </article>
      <article>
        <ref-id>A187544</ref-id>
        <pubmed-id>15373936</pubmed-id>
        <citation>Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH: Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004 Oct;58(4):429-32. doi: 10.1111/j.1365-2125.2004.02145.x.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L9623</ref-id>
        <title>Vumerity FDA label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf</url>
      </link>
      <link>
        <ref-id>L9626</ref-id>
        <title>Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis</title>
        <url>https://www.prnewswire.com/news-releases/biogen-and-alkermes-announce-fda-approval-of-vumerity-diroximel-fumarate-for-multiple-sclerosis-300947775.html</url>
      </link>
      <link>
        <ref-id>L9629</ref-id>
        <title>FDA Clears More Tolerable Diroximel Fumarate (Vumerity) for MS</title>
        <url>https://www.medscape.com/viewarticle/920574</url>
      </link>
      <link>
        <ref-id>L9632</ref-id>
        <title>Drugs.com: FDA approves Vumerity</title>
        <url>https://www.drugs.com/newdrugs/fda-approves-vumerity-diroximel-fumarate-multiple-sclerosis-5096.html</url>
      </link>
      <link>
        <ref-id>L9638</ref-id>
        <title>Dimethyl fumarate FDA Label</title>
        <url>https://www.tecfidera.com/content/dam/commercial/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Adv Ther (2019) 36:3154–3165 https://doi.org/10.1007/s12325-019-01085-3</synthesis-reference>
  <indication>Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults; specifically active secondary progressive disease and clinically isolated syndrome, as well as relapsing-remitting MS.[L9623,L9629,L9632]</indication>
  <pharmacodynamics>Diroximel fumarate relieves the neurological symptoms of relapsing MS with less gastrointestinal effects than its bioequivalent counterpart, dimethyl fumarate.[A187532,L9623] It is important to note that diroximel fumarate can cause angioedema, anaphylaxis, hepatotoxicity, flushing, lymphopenia, and Progressive Multifocal Leukoencephalopathy (PML).[L9623] &#13;
&#13;
Discontinue diroximel fumarate immediately if PML is suspected or if anaphylaxis or angioedema occur. Liver function and total bilirubin should be tested prior to initiating diroximel fumarate and during treatment. A complete blood count (CBC) should be obtained prior to starting diroximel fumarate, after the first 6 months of administration, and at subsequent intervals of 6 to 12 months following this period. Suspend treatment if lymphocyte counts are measured to be less than 0.5 × 109/L for more than 6 months.[L9623]</pharmacodynamics>
  <mechanism-of-action>Currently, the mechanism of action of this drug in MS is not fully understood.[L9623] Diroximel fumarate is hypothesized to regulate cell signaling pathways, causing beneficial immune and neuroprotective effects.[A187532] Monomethyl fumarate (MMF) is the active metabolite of diroximel fumarate, and activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in humans. This pathway occurs as a response to oxidative stress in cells.[L9623]&#13;
&#13;
In addition to the above, MMF is a nicotinic acid receptor agonist in the laboratory setting. The relevance of this finding to the treatment of MS is unknown at this time.[L9623] The mechanism by which this drug leads to less gastrointestinal effects is purported to be due to its lack of a methanol leaving group in its chemical structure, and substitution with inert 2-hydroxyethyl succinimide.[A187532]</mechanism-of-action>
  <toxicity>Currently, an MSDS for diroximel fumarate is unavailable. The MSDS for its bioequivalent counterpart, dimethyl fumarate,  indicates an oral LD50 of 2,240 mg/kg in rats.[MSDS]&#13;
&#13;
There is no information regarding overdose on the FDA label for diroximel fumarate. Cases of overdose with its bioequivalent counterpart, dimethyl fumarate, have been reported in the literature, and symptoms reflect the adverse effects of this drug. These symptoms include nausea, vomiting, diarrhea, and flushing, among others.[L9632,L8638] Currently there is no antidote to an overdose with diroximel fumarate or dimethyl fumarate. Symptomatic and supportive management are the only options up to this date if an overdose should occur.[L9638]</toxicity>
  <metabolism>Esterases heavily metabolize diroximel fumarate, as well as its bioequivalent drug, dimethyl fumarate, in the liver.[A187544] These enzymes are present in high quantities in the gastrointestinal tract, tissues, and blood.  Esterase metabolism of this drug produces the active metabolite, mono methyl fumarate (MMF), before it moves to the systemic circulation. In addition, the major inactive metabolite, 2-hydroxyethyl succinimide (HES) is produced along with small amounts of methanol, and another inactive metabolite, RDC-8439.[A187532,L9623] Following esterase metabolism, the  tricarboxylic acid (TCA)cycle further metabolizes MMF. The major metabolites of MMF in plasma include fumaric acid, citric acid, and glucose.[A187544,L9623]  It is important that methanol is a major metabolite of dimethyl fumarate metabolism, but a minor metabolite of diroximel fumarate metabolism, conferring its lower risk of gastrointestinal effects.[A187532]</metabolism>
  <absorption>Diroximel fumarate is rapidly absorbed in the gastrointestinal tract following administration, like its bioequivalent drug, dimethyl fumarate.[A187544] The median Tmax of monomethyl fumarate (MMF) after oral administration ranges from 2.5-3 hours with a mean Cmax of 2.11 mg/L[L9623]. The bioequivalent drug, dimethyl fumarate, administered to healthy volunteers also shows a similar mean Tmax and Cmax.[A187544]&#13;
&#13;
The average steady state concentration of this metabolite is estimated at 8.32 mg.hr/L after it is administered twice a day in patients with MS.[L9623] The mean AUC0–∞ of the active metabolite is 88mg × min L−1. Food appears to significantly reduce the Cmax of diroximel fumarate's active metabolite, MMF, when compared to administration in the fasted state.[A187544,L9623]</absorption>
  <half-life>The terminal half-life of monomethyl fumarate (MMF), diroximel fumarate's active metabolite, is estimated to be 1 hour.[A187544,L9623]</half-life>
  <protein-binding>Plasma protein binding of MMF, the active metabolite of diroximel fumarate, ranges from 27-45%.[L9623]</protein-binding>
  <route-of-elimination>Monomethyl fumarate is eliminated as carbon dioxide through expired breath. Negligible amounts, under 0.3% of the ingested dose, are measured in urine.[L9623] The inactive metabolite, 2-hydroxyethyl succinimide (HES), representing 58-63% of the ingested dose, is excreted in urine.[L9623]</route-of-elimination>
  <volume-of-distribution>The apparent volume of distribution ranges from 72L to 83L.[L9623] Monomethyl fumarate (MMF), the active metabolite of diroximel fumarate, crosses the blood brain barrier.[A187529]</volume-of-distribution>
  <clearance>No clearance information is available on the FDA label for diroximel fumarate[L9623], however, clinical study results for its active metabolite, monomethyl fumarate show a mean apparent total clearance from the plasma after oral administration of 1.54 mgL−1.[A187544]</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn/usan">Diroximel fumarate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Vumerity</name>
      <labeller>Biogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64406-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>231 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA211855</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Vumerity</name>
      <ingredients>Diroximel fumarate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Fumarates</category>
      <mesh-id>D005650</mesh-id>
    </category>
    <category>
      <category>Hepatotoxic Agents</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>231 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB14783.pdf?1572624462</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB08908</drugbank-id>
      <name>Dimethyl fumarate</name>
      <description>The serum concentration of Monomethyl fumarate, an active metabolite of Diroximel fumarate, can be increased when used in combination with Dimethyl fumarate.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.08</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.50e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 4-methyl (2E)-but-2-enedioate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2R)-14-fluoro-2-methyl-6,9,10,19-tetraazapentacyclo[14.2.1.0^{2,6}.0^{8,18}.0^{12,17}]nonadeca-1(18),8,12(17),13,15-pentaen-11-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>255.226</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>255.074287143</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C11H13NO6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>YIMYDTCOUQIDMT-SNAWJCMRSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>89.98</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>59.35</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>23.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-6.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>102-106</value>
      <source>https://www.nwmissouri.edu/naturalsciences/sds/d/Dimethyl%20fumarate.pdf</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>192-193</value>
      <source>https://www.nwmissouri.edu/naturalsciences/sds/d/Dimethyl%20fumarate.pdf</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.74</value>
      <source>https://www.tecfidera.com/content/dam/commercial/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>57423290</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL3989944</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB14783</drugbank-id>
        <name>Diroximel fumarate</name>
      </left-element>
      <right-element>
        <drugbank-id>DB14219</drugbank-id>
        <name>Monomethyl fumarate</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0009561</drugbank-id>
          <name>Liver esterases</name>
          <uniprot-id/>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB14783</drugbank-id>
        <name>Diroximel fumarate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02865</drugbank-id>
        <name>2-hydroxyethyl succinimide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0009561</drugbank-id>
          <name>Liver esterases</name>
          <uniprot-id/>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB14783</drugbank-id>
        <name>Diroximel fumarate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00536</drugbank-id>
        <name>Methanol</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0009561</drugbank-id>
          <name>Liver esterases</name>
          <uniprot-id/>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB14783</drugbank-id>
        <name>Diroximel fumarate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02866</drugbank-id>
        <name>RDC-8439</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0009561</drugbank-id>
          <name>Liver esterases</name>
          <uniprot-id/>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB14219</drugbank-id>
        <name>Monomethyl fumarate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02867</drugbank-id>
        <name>Glucose</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB14219</drugbank-id>
        <name>Monomethyl fumarate</name>
      </left-element>
      <right-element>
        <drugbank-id>DB01677</drugbank-id>
        <name>Fumaric Acid</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB14219</drugbank-id>
        <name>Monomethyl fumarate</name>
      </left-element>
      <right-element>
        <drugbank-id>DB04272</drugbank-id>
        <name>Citric acid</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="2">
      <id>BE0000411</id>
      <name>Neuronal acetylcholine receptor subunit alpha-10</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L9623</ref-id>
            <title>Vumerity FDA label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9GZZ6" source="Swiss-Prot">
        <name>Neuronal acetylcholine receptor subunit alpha-10</name>
        <general-function>Receptor binding</general-function>
        <specific-function>Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma.</specific-function>
        <gene-name>CHRNA10</gene-name>
        <locus>11p15.5</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>238-258
268-288
302-322
429-449</transmembrane-regions>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi>7.97</theoretical-pi>
        <molecular-weight>49704.295</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:13800</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRNA10</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ278118</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>12053839</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>470</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>470</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9GZZ6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACH10_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NACHR alpha-10</synonym>
          <synonym>NACHRA10</synonym>
          <synonym>Nicotinic acetylcholine receptor subunit alpha-10</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010285|Neuronal acetylcholine receptor subunit alpha-10
MGLRSHHLSLGLLLLFLLPAECLGAEGRLALKLFRDLFANYTSALRPVADTDQTLNVTLE
VTLSQIIDMDERNQVLTLYLWIRQEWTDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYN
KADAQPPGSASTNVVLRHDGAVRWDAPAITRSSCRVDVAAFPFDAQHCGLTFGSWTHGGH
QLDVRPRGAAASLADFVENVEWRVLGMPARRRVLTYGCCSEPYPDVTFTLLLRRRAAAYV
CNLLLPCVLISLLAPLAFHLPADSGEKVSLGVTVLLALTVFQLLLAESMPPAESVPLIGK
YYMATMTMVTFSTALTILIMNLHYCGPSVRPVPAWARALLLGHLARGLCVRERGEPCGQS
RPPELSPSPQSPEGGAGPPAGPCHEPRCLCRQEALLHHVATIANTFRSHRAAQRCHEDWK
RLARVMDRFFLAIFFSMALVMSLLVLVQAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010286|Neuronal acetylcholine receptor subunit alpha-10 (CHRNA10)
ATGCCGGCGCGGCGGCGCGTGCTCACCTACGGCTGCTGCTCCGAGCCCTACCCCGACGTC
ACCTTCACGCTGCTGCTGCGCCGCCGCGCCGCCGCCTACGTGTGCAACCTGCTGCTGCCC
TGCGTGCTCATCTCGCTGCTTGCGCCGCTCGCCTTCCACCTGCCTGCCGACTCAGGCGAG
AAGGTGTCGCTGGGCGTCACCGTGCTGCTGGCGCTCACCGTCTTCCAGTTGCTGCTGGCC
GAGAGCATGCCACCGGCCGAGAGCGTGCCGCTCATCGGGAAGTACTACATGGCCACTATG
ACCATGGTCACATTCTCAACAGCACTCACCATCCTTATCATGAACCTGCATTACTGTGGT
CCCAGTGTCCGCCCAGTGCCAGCCTGGGCTAGGGCCCTCCTGCTGGGACACCTGGCACGG
GGCCTGTGCGTGCGGGAAAGAGGGGAGCCCTGTGGGCAGTCCAGGCCACCTGAGTTATCT
CCTAGCCCCCAGTCGCCTGAAGGAGGGGCTGGCCCCCCAGCGGGCCCTTGCCACGAGCCA
CGATGTCTGTGCCGCCAGGAAGCCCTACTGCACCACGTAGCCACCATTGCCAATACCTTC
CGCAGCCACCGAGCTGCCCAGCGCTGCCATGAGGACTGGAAGCGCCTGGCCCGTGTGATG
GACCGCTTCTTCCTGGCCATCTTCTTCTCCATGGCCCTGGTCATGAGCCTCCTGGTGCTG
GTGCAGGCCCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of mechanical stimulus involved in sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inner ear morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0009561</id>
      <name>Liver esterases</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187541</ref-id>
            <pubmed-id>24139424</pubmed-id>
            <citation>Sheikh SI, Nestorov I, Russell H, O'Gorman J, Huang R, Milne GL, Scannevin RH, Novas M, Dawson KT: Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013 Oct;35(10):1582-1594.e9. doi: 10.1016/j.clinthera.2013.08.009.</citation>
          </article>
          <article>
            <ref-id>A187544</ref-id>
            <pubmed-id>15373936</pubmed-id>
            <citation>Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH: Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004 Oct;58(4):429-32. doi: 10.1111/j.1365-2125.2004.02145.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L9623</ref-id>
            <title>Vumerity FDA label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>